Informations générales (source: ClinicalTrials.gov)
Evaluation of Plasma Vitamin C Levels in a Population of Chronic Rheumatism in Immuno-Rheumatology (VitCRIC)
Interventional
N/A
Centre Hospitalier Universitaire de Nice (Voir sur ClinicalTrials)
juin 2022
décembre 2024
29 juin 2024
Scurvy is an almost forgotten carential pathology, caused by a deep vitamin C (or
ascorbic acid) deficiency, a priori exceptional in industrialized countries. According to
the French National Authority for Health standards, hypovitaminosis C is defined as a
plasma vitamin C level of less than 23 μmol/L. This deficiency would affect 5 to 10% of
the general population in industrialized countries and from 17% (clinical scurvy) to 47%
(biological hypovitaminosis C) of vulnerable populations (malnutrition, hospitalized
patients...). Vitamin C is essential for collagen synthesis. It plays a cofactor role in
the synthesis of catecholamines precursors and takes action in synthesis of certain amino
acids.
In rheumatology, pain is a recurring reason for consultation. In a context of treated
chronic inflammatory rheumatism (RIC), while most of patients seem in remission or in
reduced activity of their disease, all real-life studies show that 30 to 40% of them
complain of residual pain, 70% of chronic fatigue and 20-25% of symptoms similar to
secondary fibromyalgia. Currently, authors suggest the interest of vitamin C analgesic
properties, especially in musculoskeletal pain, due to the role of ascorbic acid in
neurotransmitters. Vitamin C would act as a cofactor for a family of biosynthetic and
regulatory metalloenzymes. Thus, the authors suggest the potential of vitamin C in an
analgesic mechanism involving the biosynthesis of opioid peptides.
Etablissements
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHU de Nice - 06000 - Nice - Alpes Maritimes - France | Nathalie THIEULIE | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- patient over 18 years-old,
- followed for chronic inflammatory rheumatism (RIC): spondylo-arthritis (including
spondylitis and psoriatic rheumatism) and lupus,
- with RIC in remission or low activity definec according to the following criteria:
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) criteria and Bath
Ankylosing Spondylitis Fonctional Index (BASFI) questionnaire for spondylitis and
psoriatic rheumatism, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
2K score for lupus,
- having given written consent after written and oral information,
- member of the social security system,
- basic treatment for the disease not modified for at least 6 months, without
modification at baseline
- persistence of painful complaints not objectively explained by his RIC.
- patient over 18 years-old,
- followed for chronic inflammatory rheumatism (RIC): spondylo-arthritis (including
spondylitis and psoriatic rheumatism) and lupus,
- with RIC in remission or low activity definec according to the following criteria:
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) criteria and Bath
Ankylosing Spondylitis Fonctional Index (BASFI) questionnaire for spondylitis and
psoriatic rheumatism, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
2K score for lupus,
- having given written consent after written and oral information,
- member of the social security system,
- basic treatment for the disease not modified for at least 6 months, without
modification at baseline
- persistence of painful complaints not objectively explained by his RIC.
- pregnant or nursing patient,
- patient protected by law or under guardianship or curatorship, or not able to
participate in a clinical trial under L.1121-16 article of French Public Health
Regulations,
- patient participating in or having participated in another drug clinical trial in
the month prior to inclusion.